Probi is a leading player in probiotic research and the development of effective, well-documented probiotics.
The company’s research areas are gastrointestinal health, immunology, the metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the fields of Functional Food and Consumer Healthcare.
In 2012, revenues totalled MSEK 100, of which the majority comprised royalty revenues. The Probi share is listed on the NASDAQ OMX Nordic Exchange Stockholm, Small Cap. Probi has about 5,000 shareholders.